GlassScriptPhysician profile
Mckenzie A Jones
NPI 1821193806
$6,329.13
in general payments reported to CMS, 2019-2025
24 companies · $2,691 in 2025
The $2,691 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.85 · 2022: $42.73 · 2023: $484 · 2024: $3,058 · 2025: $2,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,055 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,054.76 |
| Education | $178.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,922.78 | 2021-2025 | |
| Janssen Biotech, INC. | $785.24 | 2021-2025 | Tremfya, Stelara, Simponi |
| Janssen Pharmaceuticals, INC | $466.69 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Regeneron Healthcare Solutions, INC. | $394.65 | 2024-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $312.33 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $282.35 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $267.26 | 2022-2025 | Sotyktu |
| Incyte Corporation | $226.60 | 2024-2025 | Opzelura |
| Ucb, INC. | $210.59 | 2024-2025 | Bimzelx |
| Axsome Therapeutics, INC. | $189.89 | 2024-2025 | Auvelity |
| Genzyme Corporation | $154.06 | 2024-2025 | |
| Lilly USA, LLC | $144.28 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $141.05 | 2021-2025 | |
| Abiomed | $124.96 | 2024 | Impella |
| Astellas Pharma US INC | $124.65 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $118.02 | 2023 | Ingrezza |
| Galderma Laboratories, L.P. | $107.22 | 2024-2025 | Nemluvio, Aklief |
| Amgen INC. | $99.59 | 2023-2025 | Otezla, Otezla |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.11 | 2024 | Rexulti |
| Arcutis Biotherapeutics, INC. | $67.41 | 2024-2025 | Zoryve |
| Organon LLC | $30.26 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.03 | 2024 | Spevigo |
| Leo Pharma INC. | $26.10 | 2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.01 | 2024 | Siliq, Duobrii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.